Fig. 6

Injection of the Siglec-15 neutralizing antibody prevented bone loss in estrogen-depleted osteoporotic mice. All data in this figure are derived from 5-month-old C57BL/6 mice that underwent OVX at 3 months old and were treated with NP-149 (control antibody), NP-158 (Siglec-15 neutralizing antibody 1), or NP-159 (Siglec-15 neutralizing antibody 2) for 2 months after surgery. a Representative three-dimensional µCT images of the mouse femurs. Quantitative analysis of the µCT scan in a: b BV/TV percentage trabecular bone volume, c Tb. N trabecular number, and d Tb. Sp trabecular separation. e BV cortical bone volume, f Cor. Th cortical bone thickness. n = 5, *P < 0.05, **P < 0.01. g Representative images of TRAP staining of the distal femurs. Quantitative analysis of TRAP staining in the sham-operated group (h) and ovariectomy group (i). Mon-Nuc: mononuclear TRAP⁺ cells, Multi-Nuc: multinuclear TRAP⁺ cells. n = 5, **P < 0.01. j Coimmunofluorescence staining of TRAP (green) and PDGF-BB (red) in the trabecular bone of mouse distal femurs. Quantitative analysis of the ratio of TRAP/PDGF-BB double-positive fluorescent cells in TRAP⁺ cells in the sham-operated (k) and ovariectomy (l) groups. n = 5, *P < 0.05. m Representative images of immunohistological staining of osteocalcin in mouse distal femurs. Quantitative analysis of osteocalcin staining in the sham-operated (n) or OVX (o) groups. n = 5, *P < 0.05